Sanofi drops diabetes, CV programs to focus on growth drivers

As part of its pivot towards specialty medicines and vaccines, Sanofi (Euronext:SAN; NASDAQ:SNY) said it is cutting a dozen programs from its clinical pipeline, including two diabetes candidates and

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE